Allarity Therapeutics, a Phase 2 clinical-stage pharmaceutical company, announced the acceptance of its patent application in Australia for the Drug Response Predictor (DRP®) companion diagnostic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results